Thanks Hottod for a great analysis again! I found your thoughts very insightful.
Agree with you that it would be unfortunate if Trofinitide was priced too high. Even if insurance companies are willing to cover 7 figures in the US I can't help feeling a very high price must end up reducing the number of patients who can access the treatment long term. I actually have a 13 yr old niece in New Zealand with Retts (a pretty severe case too - unable to talk or move independently at all) and worry about whether Trofinitide will be affordable for them - the higher the price the more likely NZ govt might refuse to fund...
Putting on my investor hat again your analysis really does make one feel very positive about Trofinitide (and NNZ-2591). We just have to wait for the pieces to come into place now.
- Forums
- ASX - By Stock
- NEU
- A De-risked bio-tech with 4X upside - Karst Peak Capital
A De-risked bio-tech with 4X upside - Karst Peak Capital, page-64
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.648B |
Open | High | Low | Value | Volume |
$20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 782 | $20.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.72 | 1021 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 782 | 20.610 |
2 | 3495 | 20.600 |
2 | 649 | 20.590 |
2 | 1774 | 20.570 |
1 | 145 | 20.550 |
Price($) | Vol. | No. |
---|---|---|
20.720 | 1021 | 2 |
20.730 | 5256 | 1 |
20.750 | 2517 | 1 |
20.790 | 782 | 1 |
20.800 | 649 | 2 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online